[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69920418D1 - Arzneimittel gegen hepatitis - Google Patents

Arzneimittel gegen hepatitis

Info

Publication number
DE69920418D1
DE69920418D1 DE69920418T DE69920418T DE69920418D1 DE 69920418 D1 DE69920418 D1 DE 69920418D1 DE 69920418 T DE69920418 T DE 69920418T DE 69920418 T DE69920418 T DE 69920418T DE 69920418 D1 DE69920418 D1 DE 69920418D1
Authority
DE
Germany
Prior art keywords
against hepatitis
hepatitis
medicine against
poly
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69920418T
Other languages
English (en)
Other versions
DE69920418T2 (de
Inventor
Kazuko Hirabayashi
Junzo Seki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of DE69920418D1 publication Critical patent/DE69920418D1/de
Application granted granted Critical
Publication of DE69920418T2 publication Critical patent/DE69920418T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69920418T 1998-03-24 1999-03-23 Arzneimittel gegen hepatitis Expired - Lifetime DE69920418T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP7605598 1998-03-24
JP7605598 1998-03-24
PCT/JP1999/001438 WO1999048531A1 (fr) 1998-03-24 1999-03-23 Nouveaux remedes contre l'hepatite

Publications (2)

Publication Number Publication Date
DE69920418D1 true DE69920418D1 (de) 2004-10-28
DE69920418T2 DE69920418T2 (de) 2005-10-06

Family

ID=13594103

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920418T Expired - Lifetime DE69920418T2 (de) 1998-03-24 1999-03-23 Arzneimittel gegen hepatitis

Country Status (12)

Country Link
US (1) US7205282B1 (de)
EP (1) EP1064950B1 (de)
JP (1) JP3804452B2 (de)
KR (1) KR100520738B1 (de)
CN (1) CN1200736C (de)
AT (1) ATE276768T1 (de)
AU (1) AU2855099A (de)
CA (1) CA2325550A1 (de)
DE (1) DE69920418T2 (de)
MY (1) MY134896A (de)
RU (1) RU2226102C2 (de)
WO (1) WO1999048531A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061032A1 (fr) * 1998-05-25 1999-12-02 Nippon Shinyaku Co., Ltd. Procede de production d'une preparation composite contenant de l'acide nucleique
CA2459373A1 (en) * 2001-09-04 2003-03-20 Nippon Shinyaku Co., Ltd. Method of evaluating efficacy of nucleic acid therapy
DE10361502A1 (de) * 2003-12-23 2005-07-28 Phenion Gmbh & Co. Kg Kosmetische oder pharmazeutische Zubereitungen enthaltend Superstruktur-bildende Nukleinsäure-Sequenzen
JP4721642B2 (ja) * 2004-01-20 2011-07-13 サントリーホールディングス株式会社 肝障害を伴う肝臓疾患の予防又は改善剤
WO2006129594A1 (ja) 2005-05-30 2006-12-07 Nippon Shinyaku Co., Ltd. 核酸含有複合体製剤の製造方法
EP2119738B1 (de) 2007-02-05 2014-04-16 Nippon Shinyaku Co., Ltd. Polyethylenglykolderivat
CN101686990A (zh) * 2007-03-19 2010-03-31 小原道法 抗病毒剂
KR20110031168A (ko) * 2008-06-19 2011-03-24 니뽄 신야쿠 가부시키가이샤 약물 담체
EA019268B1 (ru) * 2010-12-01 2014-02-28 Общество С Ограниченной Ответственностью "Анвилаб" Комбинированное средство, обладающее гепатопротекторным действием
CN105824410B (zh) * 2016-02-22 2017-09-15 维沃移动通信有限公司 一种自动滚屏阅读方法及移动终端
CN110433173A (zh) * 2019-07-19 2019-11-12 成都市海通药业有限公司 聚肌胞注射液及用于降低聚肌胞注射液内毒素的方法
CN116354836A (zh) * 2022-03-25 2023-06-30 深圳市新合生物医疗科技有限公司 阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140761A (en) * 1977-04-11 1979-02-20 The United States Of America As Represented By The Department Of Health, Education & Welfare Modification of hepatitis B virus infection in chronic carriers of hepatitis B surface antigen
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5298614A (en) * 1986-01-06 1994-03-29 Nippon Shinyaku Co. Ltd. Size limited double stranded poly I poly(cytidylate/4-thiouridylate)
EP0685234B1 (de) 1993-02-19 2000-05-10 Nippon Shinyaku Company, Limited Arzneistoffzusammensetzung, die ein nukleinsäurecopolymer enthält
TW524693B (en) 1997-10-16 2003-03-21 Nippon Shinyaku Co Ltd Cancer cell nuclease activator

Also Published As

Publication number Publication date
KR20010042093A (ko) 2001-05-25
CN1294518A (zh) 2001-05-09
AU2855099A (en) 1999-10-18
RU2226102C2 (ru) 2004-03-27
WO1999048531A1 (fr) 1999-09-30
EP1064950B1 (de) 2004-09-22
CA2325550A1 (en) 1999-09-30
MY134896A (en) 2007-12-31
US7205282B1 (en) 2007-04-17
KR100520738B1 (ko) 2005-10-12
DE69920418T2 (de) 2005-10-06
EP1064950A1 (de) 2001-01-03
JP3804452B2 (ja) 2006-08-02
ATE276768T1 (de) 2004-10-15
EP1064950A4 (de) 2002-11-27
CN1200736C (zh) 2005-05-11

Similar Documents

Publication Publication Date Title
DE4497905T1 (de) Pharmazeutische Zusammensetzung zur Prävention und Behandlung des Motion-Sickness-Syndroms
AU7476894A (en) Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
BG103786A (bg) Състав и метод за профилактика и лечение на нiv и други инфекциозни заболявания при човека
DE69920418D1 (de) Arzneimittel gegen hepatitis
PL372925A1 (en) Prevention and treatment of restenosis by local administration of drug
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
HUP0104709A2 (hu) Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására
ATE207743T1 (de) Pharmazeutische präparate zur gezielten behandlung von morbus crohn und colitis ulcerosa
RS114004A (en) Modified 2' and 3'-nucleoside produgs for treating flaviridae infections
PT1040830E (pt) Medicamento para doencas neurodegenerativas
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
ATE141790T1 (de) Medikament zur hemmung der stickoxid-bildung
DE69527506D1 (de) Delta 12,16-isotaxol analoge mit antineoplastischer wirkung und pharmazeutische zusammensetzungen sie enthaltend
DE60016460D1 (de) Verwendungen und zusammenstellungen von nitratestern als sedativa
BG105302A (en) Means for improving cognition
NZ513650A (en) Pharmaceutical composition for the treatment of urinary incontinence, motion sickness and vertigo
SI0770384T1 (en) Solid, anhydrous, pharmaceutical compositions for vaginal use
SE9201930D0 (sv) Gastric antibacterial treatment
DE60031016D1 (de) Verwendung von Antiseptika zur Herstellung von Arzneimitteln zur Prophylaxe und Behandlung von Entzündungen im Korperinneren des Menschen
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
EA199900963A1 (ru) Лекарственные формы сертралина в виде раствора, заключенного в желатиновые капсулы

Legal Events

Date Code Title Description
8364 No opposition during term of opposition